Navigation Links
New link identified for bipolar disorder
Date:6/17/2010

Lithium has been established for more than 50 years as one of the most effective treatments for manic depression, clinically termed bipolar disorder.

However, scientists have never been entirely sure exactly why it is beneficial.

Now, new research from Cardiff University scientists suggests a possible mechanism for why Lithium works, opening the door for better understanding of the illness and potentially more effective treatments.

Laboratory studies with cells have shown that an enzyme known as prolyl oligopeptidase (PO) controls a set of genes that determine sensitivity to lithium. Among these genes is ImpA2, which like PO activity itself, has been associated with differences in some bipolar patients. These results reveal a new mechanistic link that could explain these changes in these patients.

Professor Adrian Harwood of Cardiff School of Biosciences, who led the research, said: "We still cannot say definitively how lithium can help stabilise bipolar disorder. However, our research has uncovered a new cell signalling process with links to bipolar disorder.

"This introduces a new mechanism and more candidate genes whose study could lead to greater understanding of the causes of bipolar disorder, better diagnostic tests and new types of drugs that are more effective and have fewer side effects than Lithium does at present."

The research, funded by the Wellcome Trust, is published in the international journal PLoS ONE.


'/>"/>

Contact: Stephen Rouse
Rouses@cardiff.ac.uk
44-292-087-5596
Cardiff University
Source:Eurekalert

Page: 1

Related biology news :

1. Key mechanism identified in metastatic breast cancer
2. Biological link between stress, anxiety and depression identified for the first time
3. New genetic risk factors for aneurysms identified by Yale-led team
4. Autism susceptibility genes identified
5. Structure of insulins docking point identified
6. Newly identified growth factor promotes stem cell growth, regeneration
7. Cell of origin identified for common type of breast cancer
8. Genetic risk factor identified for Parkinsons disease
9. Canine compulsive disorder gene identified
10. Canine compulsive disorder gene identified in dogs
11. Genetic causes identified for disturbances in lipid metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: